Tacalcitol

Summary

Tacalcitol (CHEMBL2105611) is an approved small-molecule vitamin D receptor agonist (ATC D05AX04) targeting VDR; indicated across 2 conditions including psoriasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D05AX04
• Targets: 1 (VDR)
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 416.6 Da · C27H44O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105611
Name	Tacalcitol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5283734
ChEBI	CHEBI:32176
ATC	D05AX04
Molecular formula	C27H44O3
Molecular weight	416.6
InChIKey	BJYLYJCXYAMOFT-RSFVBTMBSA-N

SMILES: C[C@H](CC[C@H](C(C)C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C

IUPAC name: trans-(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R,5R)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol

ChEBI definition: A hydroxy seco-steroid that is calciol which carries hydroxy groups at positions 1S and 24R. It is a vitamin D3 analog which is used for the treatment of psoriasis vulgaris in adults, especially on the scalp.

Pharmacological roles (ChEBI): antipsoriatic, vitamin D receptor agonist, antineoplastic agent.

Also known as: Bonalfa, Curatoderm, Tacalcitol, TACALCITOL, tacalcitol

Patent coverage: 719 distinct patent families (2,309 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
VDR	Vitamin D receptor	Agonist	8.5	0.2%	P11473

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Vitamin D3 receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
VDR	8.15	EC50	7.05	nM	CHEMBL_ACT_13479426

Target pathways

Aggregated over 1 target gene(s): VDR.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Vitamin D (calciferol) metabolism	1	VDR
Nuclear Receptor transcription pathway	1	VDR
SUMOylation of intracellular receptors	1	VDR

Dominant GO biological processes

GO term	Targets
negative regulation of transcription by RNA polymerase II	1
cell morphogenesis	1
skeletal system development	1
calcium ion transport	1
intracellular calcium ion homeostasis	1
lactation	1
negative regulation of cell population proliferation	1
positive regulation of gene expression	1
negative regulation of keratinocyte proliferation	1
cell differentiation	1
positive regulation of bone mineralization	1
intracellular receptor signaling pathway	1
phosphate ion transmembrane transport	1
nuclear receptor-mediated bile acid signaling pathway	1
mRNA transcription by RNA polymerase II	1

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psoriasis	4	MONDO:0005083	EFO:0000676

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00640822	PHASE3	COMPLETED	Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds
NCT00670241	PHASE3	COMPLETED	Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

9 molecules share ≥1 primary target. Top 9 by shared-target count:

Molecule	Source	Status	Shared targets
CALCIPOTRIENE	ChEMBL	Phase 4 (approved)	VDR
CALCITRIOL	ChEMBL	Phase 4 (approved)	VDR
CHOLECALCIFEROL	ChEMBL	Phase 4 (approved)	VDR
DOXERCALCIFEROL	ChEMBL	Phase 4 (approved)	VDR
CURCUMIN	ChEMBL	Phase 3	VDR
MAXACALCITOL	ChEMBL	Phase 3	VDR
SEOCALCITOL	ChEMBL	Phase 3	VDR
TAUROLITHOCHOLIC ACID	ChEMBL	Phase 3	VDR
chenodiol	PubChem	Approved	VDR